Protagonist Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from TD Cowen maintained a Buy rating on the stock and has a $90.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tara Bancroft’s rating is based on several promising developments at Protagonist Therapeutics. The company is advancing its drug Icotrokinra, which has shown a best-in-class profile among oral therapies for psoriasis, with a U.S. launch expected in the second half of 2026. The drug has demonstrated significant efficacy in Phase III trials, and its potential to become a leading oral standard of care is supported by strong interest from dermatology experts and investors.
Bancroft also highlights the strategic progress of Protagonist’s pipeline, including the anticipated launch of Rusfertide by late 2026 and ongoing Phase III trials for Icotrokinra in ulcerative colitis and Crohn’s disease. Additionally, the company is working on other promising candidates like PN-881 and PN-477, with further developments expected soon. These factors, combined with a discounted cash flow-based price target increase to $90, underpin Bancroft’s Buy rating for Protagonist Therapeutics.
In another report released on November 3, BTIG also maintained a Buy rating on the stock with a $82.00 price target.